We Think Some Shareholders May Hesitate To Increase Molecular Partners AG's (VTX:MOLN) CEO Compensation
Apr 11
Swiss (SMI) Biotech Industry Analysis
UpdatedApr 17, 2024
DataAggregated Company Financials
Companies6
- 7D12.6%
- 3M28.5%
- 1Y16.3%
- YTD43.2%
Over the last 7 days, the Biotech industry has risen 13%, driven by gains from Kuros Biosciences of 21%. Meanwhile, Idorsia actually underperformed within the industry, shrinking 20% in the last week. In the last 12 months, the industry was up 16%. Earnings are forecast to grow by 15% annually.
Industry Valuation and Performance
Has the Swiss Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 18 Apr 2024 | CHF443.1m | CHF67.6m | -CHF173,109,973.72 | 0.09x | -2.6x | 6.6x |
| Sat, 16 Mar 2024 | CHF341.9m | CHF67.0m | -CHF173,340,900.02 | 0.3x | -2x | 5.1x |
| Mon, 12 Feb 2024 | CHF370.7m | CHF55.4m | -CHF173,281,198.02 | 1x | -2.1x | 6.7x |
| Wed, 10 Jan 2024 | CHF328.6m | CHF317.4m | -CHF176,087,588.00 | 0.5x | -1.9x | 1x |
| Fri, 08 Dec 2023 | CHF355.4m | CHF317.9m | -CHF208,997,992.00 | n/a | -1.7x | 1.1x |
| Sun, 05 Nov 2023 | CHF280.8m | CHF318.4m | -CHF211,186,226.00 | n/a | -1.3x | 0.9x |
| Tue, 03 Oct 2023 | CHF262.4m | CHF318.6m | -CHF213,627,067.00 | n/a | -1.2x | 0.8x |
| Thu, 31 Aug 2023 | CHF299.1m | CHF316.7m | -CHF188,466,057.00 | n/a | -1.6x | 0.9x |
| Sat, 29 Jul 2023 | CHF415.5m | CHF322.5m | -CHF179,916,730.00 | n/a | -2.3x | 1.3x |
| Mon, 26 Jun 2023 | CHF310.6m | CHF331.2m | -CHF180,840,246.00 | n/a | -1.7x | 0.9x |
| Wed, 24 May 2023 | CHF340.9m | CHF331.7m | -CHF183,252,267.00 | n/a | -1.9x | 1x |
| Fri, 21 Apr 2023 | CHF433.5m | CHF481.3m | CHF8.2m | 1.6x | 52.9x | 0.9x |
| Sun, 19 Mar 2023 | CHF438.5m | CHF497.1m | CHF11.5m | 1.5x | 38x | 0.9x |
| Tue, 14 Feb 2023 | CHF480.5m | CHF493.4m | CHF14.5m | 1.7x | 33.1x | 1x |
| Thu, 12 Jan 2023 | CHF508.5m | CHF493.4m | CHF14.5m | 1.7x | 35.1x | 1x |
| Sat, 10 Dec 2022 | CHF508.7m | CHF493.4m | CHF14.5m | 1.8x | 35.1x | 1x |
| Mon, 07 Nov 2022 | CHF511.8m | CHF509.0m | CHF14.9m | 1.8x | 34.4x | 1x |
| Wed, 05 Oct 2022 | CHF532.4m | CHF504.8m | CHF15.9m | 2x | 33.4x | 1.1x |
| Fri, 02 Sep 2022 | CHF508.2m | CHF502.5m | CHF36.7m | 1.6x | 13.9x | 1x |
| Sun, 31 Jul 2022 | CHF527.0m | CHF483.8m | CHF42.3m | 1.9x | 12.5x | 1.1x |
| Tue, 28 Jun 2022 | CHF559.9m | CHF454.3m | CHF80.7m | 2.2x | 6.9x | 1.2x |
| Thu, 26 May 2022 | CHF708.9m | CHF467.9m | CHF24.7m | 2x | 28.8x | 1.5x |
| Sat, 23 Apr 2022 | CHF1.0b | CHF295.6m | -CHF142,004,500.00 | 2x | -7.1x | 3.4x |
| Mon, 21 Mar 2022 | CHF1.2b | CHF285.6m | -CHF139,004,039.00 | 2x | -8.7x | 4.2x |
| Wed, 16 Feb 2022 | CHF1.4b | CHF283.1m | -CHF138,837,100.00 | 1.8x | -10.1x | 4.9x |
| Fri, 14 Jan 2022 | CHF4.9b | CHF315.0m | -CHF659,364,453.00 | 1.5x | -7.4x | 15.4x |
| Sun, 12 Dec 2021 | CHF3.8b | CHF317.8m | -CHF658,969,179.00 | 1.5x | -5.8x | 12x |
| Tue, 09 Nov 2021 | CHF4.0b | CHF316.0m | -CHF659,223,496.00 | 2.3x | -6.1x | 12.8x |
| Thu, 07 Oct 2021 | CHF4.9b | CHF287.8m | -CHF590,795,275.00 | 2.2x | -8.3x | 17.1x |
| Sat, 04 Sep 2021 | CHF5.5b | CHF306.0m | -CHF612,309,374.80 | 1.1x | -9x | 17.9x |
| Mon, 02 Aug 2021 | CHF5.4b | CHF306.0m | -CHF612,309,374.80 | 1.1x | -8.9x | 17.7x |
| Thu, 06 May 2021 | CHF5.5b | CHF352.3m | -CHF535,605,963.80 | 1.1x | -10.4x | 15.7x |
Price to Earnings Ratio
-10.4x
Current Industry PE
- Investors are optimistic on the Swiss Biotechs industry, and appear confident in long term growth rates.
- The 3-year average PS ratio of 5.5x is lower than the industry's current PS ratio of 6.6x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have improved over the last three years.
- Meanwhile revenues for these companies have declined 42% per year.
- This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.
Industry Trends
Which industries have driven the changes within the Swiss Healthcare industry?
| CH Market | -0.80% | |
| Healthcare | 0.40% | |
| Biotech | 12.59% | |
| Biotech | 12.59% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| KURN Kuros Biosciences | CHF7.67 | 6.4% +CHF17.0m | 508.7% | PS8.4x | |
| BSLN Basilea Pharmaceutica | CHF41.70 | 2.0% +CHF9.6m | -6.3% | PE47.9x | |
| SANN Santhera Pharmaceuticals Holding | CHF9.85 | 1.4% +CHF1.3m | 53.9% | PS17.6x |
